Trials / Recruiting
RecruitingNCT06868628
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
A Phase 2a Study to Evaluate Microglial Activation, Safety, and Clinical Effects of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- Tiziana Life Sciences LTD · Industry
- Sex
- All
- Age
- 30 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Foralumab Nasal | Foralumab is an anti-CD3 monoclonal antibody administered as a nasal spray. Participants will complete eight 3-week dosing cycles over the study. During each cycle, Foralumab will be administered intranasally three times per week for the first two weeks, with no administration in the third week. |
Timeline
- Start date
- 2025-05-19
- Primary completion
- 2027-04-01
- Completion
- 2027-04-01
- First posted
- 2025-03-11
- Last updated
- 2025-09-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06868628. Inclusion in this directory is not an endorsement.